Loading...
•
Mar 31, 2025
Edwards Lifesciences Q1 2025 Earnings Report
Edwards Lifesciences reported solid financial performance in Q1 2025 with increased revenue and profitability.
Key Takeaways
The company delivered a strong start to 2025, with notable growth in TMTT and steady gains in TAVR. EPS and net income improved, bolstered by product adoption and operational efficiency.
Revenue grew to $1.41 billion, a 6.2% increase year-over-year.
Transcatheter Mitral and Tricuspid Therapies (TMTT) surged 58% to $115 million.
Adjusted EPS reached $0.64, exceeding expectations.
Gross profit margin improved slightly to 78.7%.
Revenue by Segment
Revenue by Geographic Location
Forward Guidance
Edwards Lifesciences reaffirmed its 2025 EPS and sales guidance, with optimism around product momentum despite macroeconomic headwinds.
Positive Outlook
- Raised 2025 TMTT sales guidance to $530M–$550M.
- Total 2025 sales now expected to be $5.7B–$6.1B.
- Reaffirmed full-year adjusted EPS guidance of $2.40–$2.50.
- Continued global adoption of new technologies like SAPIEN M3 and EVOQUE.
- Strong start to the year supports confidence in long-term growth strategy.
Challenges Ahead
- Expectations of margin pressure from weakening dollar.
- Tariff impacts could increase operational costs.
- Pending acquisition of JenaValve may bring dilution.
- Limited growth in Surgical segment (only 1% YoY).
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...